Apathy Clinical Trial
Official title:
In Vivo Involvement of the Cholinergic and Dopaminergic Systems in the Pathophysiology of Apathy.
Apathy is a neurocognitive syndrome characterized by reduced goal-directed behaviors, contributing to decreased patient and caregiver quality of life. Apathy pathophysiology involves disruption of cortico-striato-thalamo-cortical loops, modulated by several neurotransmitter systems including dopamine and acetylcholine, thus complexifying pharmacological management. Post-stroke apathy (PSA) can provide a proper in vivo model to study the underlying neurochemical substrates of apathy as a syndrome. The present project aims to provide a better characterization of the cholinergic and dopaminergic functioning in apathy as a syndrome. In order to precise the respective alterations of these two systems, investigators will use a positron emission tomography (PET) molecular imaging of dopaminergic (with [18F]-FDOPA, a marker of the decarboxylating enzyme of dopamine) and - for the first time in apathetic patients - cholinergic (with [18F]-FEOBV, a marker of the vesicular acetylcholine transporter) transmissions in 15 apathetic and 15 unapathetic patients 3 months after stroke, without overlapping depression. This dual imaging study may provide help in guiding therapeutic management of PSA. The functional network analysis allowed by functional MRI is crucial to complement regional neurotransmitter deficits observed with PET. Altogether, a multimodal approach in apathy, combining PET and MRI, can allow identifying which circuits of the cortico-striato-thalamo-cortical loops are disrupted and how these circuits are modulated by other neurotransmitters.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03272230 -
Assessment of Apathy in a Real-life Situation, With a Video and Sensors-based System
|
N/A | |
| Recruiting |
NCT03293537 -
Dementia Associated Apathy.
|
N/A | |
| Terminated |
NCT01825577 -
Exploring the Use of Transdermal Methylphenidate to Reduce Fall Risk in Patients With Dementia.
|
Phase 4 | |
| Withdrawn |
NCT00792662 -
Improving Function, Quality of Life, Glycemia in Diabetics With Dementia
|
Phase 4 | |
| Recruiting |
NCT03590327 -
Transcranial Magnetic Stimulation for Apathy in Mild Cognitive Impairment
|
N/A | |
| Completed |
NCT02190084 -
Repetitive Transcranial Magnetic Stimulation for Apathy in Alzheimer's Dementia
|
Phase 4 | |
| Completed |
NCT05808530 -
Cognitive Stimulation Therapy
|
N/A | |
| Completed |
NCT00767091 -
Study of Rivastigmine to Treat Parkinsonian Apathy Without Dementia
|
Phase 3 | |
| Not yet recruiting |
NCT06184165 -
Stratifying Psychoses for Personalized REpetitive TMS in Persistent NEgative Symptoms Alleviation
|
N/A | |
| Terminated |
NCT02915484 -
Transcranial Direct Current Stimulation (tDCS) in Chronic Post-Stroke Apathy
|
N/A | |
| Recruiting |
NCT01885806 -
Repetitive Transcranial Magnetic Stimulation for Apathy Treatment in Alzheimer's Disease
|
Phase 2 | |
| Not yet recruiting |
NCT01765257 -
Evaluation of the Efficacy of Rasagiline in Apathy in Drug-naïve Patients With Parkinson's Disease by a Multi-center Study
|
Phase 4 | |
| Recruiting |
NCT01689181 -
Apathy in Schizophrenia
|
N/A | |
| Active, not recruiting |
NCT02786667 -
Non Motors Aspects in De Novo Parkinson's Disease
|
Phase 3 | |
| Completed |
NCT01914965 -
Apathy Cure Through Bupropion in Huntington's Disease
|
Phase 2 | |
| Completed |
NCT01117181 -
Apathy in Dementia Methylphenidate Trial (ADMET)
|
Phase 2 | |
| Terminated |
NCT05182151 -
Effect of Istradefylline Treatment on Behavioral Measures of Apathy in Parkinson's Disease.
|
||
| Completed |
NCT00844090 -
The Role of Apathy in Glycemic Control
|
N/A | |
| Completed |
NCT01172145 -
Treatment of Apathy in Alzheimer's Disease With Modafinil
|
Phase 3 | |
| Completed |
NCT00456820 -
Wellbutrin XL Effects on SSRIs Induced Changes
|
Phase 4 |